Background/Aims: Abdominal bloating is a troublesome complaint due to insufficient understanding of the pathophysiology. The aim of this study was to evaluate the efficacy of rifaximin in reducing bloating associated with functional gastrointestinal disorders (FGIDs). Methods: A total of 63 patients were treated with rifaximin for FGIDs with bloating or gas-related symptoms between 2007 and 2013 at Seoul National University Bundang Hospital. Rifaximin was administered at a dose between 800 mg/day and 1,200 mg/day for 5 to 14 days. The proportion of patients who had adequate relief of global FGID symptoms and FGID-related bloating was retrospectively assessed. The response was recorded when the symptoms were reduced by at least 50% at the follow-up after treatment cessation. Results: The mean age was 56.8±14.2 years; 49.2% were females. According to Rome III criteria, 20.6% (13/63) had irritable bowel syndrome (IBS) with constipation, 9.5% (6/63) had IBS with diarrhea, 4.8% (3/63) had mixed IBS, 23.8% (15/63) had functional dyspepsia, and 12.7% (8/63) had functional bloating. Of the 51 subjects who were followed-up, 30 (58.8%) had adequate relief of global FGID symptoms and 26 (51.0%) experienced improvement of abdominal bloating after rifaximin treatment. The proportion of female was slightly higher in non-response group than in the response group (60.0% vs. 34.6%, p=0.069). Otherwise, there was no difference between the two groups. Conclusions: Despite the limitations of this retrospective study, our data confirms that rifaximin may be beneficial for abdominal bloating. Further prospective clinical trial with a larger cohort is needed. (Korean J Gastroenterol 2018;72:121-127) 
. Flow diagram of the study. After exclusion of 18 patients with organic disease, 51 patients with rifaximin treatment who had been followed-up were analyzed. d/t, due to.
including bloating, has been suggested, [4] [5] [6] and researchers have found the altered colonic flora in stool samples of IBS patients. 7, 8 Patients with bloating also have also been shown to have increased gas production from bacterial fermentation caused by small intestinal bacterial overgrowth. 9 Rifaximin is a gut-selective antibiotic with little systemic absorption and broad-spectrum activity against gram-positive and gram-negative aerobes and anaerobes. 10 The antibiotic has been increasingly used to treat IBS symptoms based on the notion that altered gastrointestinal flora or small intestinal bacterial overgrowth might cause distension symptom. 11 However, due to the lack of large-scale cohort study, the indication, dosage, or treatment duration for rifaximin remains unclear. 2 The aim of this retrospective study was to evaluate the final diagnosis profile of patients without organic disease treated with rifaximin for abdominal bloating, as well as to evaluate its response rate.
SUBJECTS AND METHODS

Patients
We retrospectively reviewed the medical charts of patients who visited Seoul National University Bundang Hospital between September 2007 and July 2013 for abdominal bloating.
After finding no improvement from using common medication, such as probiotics, prokinetics, or antispasmodics, rifaximin (Normix®, Alfa Wassermann, Bologna, Italy) was prescribed.
Patients who were found to have organic gastrointestinal disorder were excluded (Fig. 1 ). This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital, Korea (IRB No. B-1801/445-108).
Chart review
The clinical manifestations and final diagnosis according to the Rome III criteria were reviewed. Patients were classified as having irritable bowel syndrome (IBS), functional dyspepsia, or combined FGID. Those who did not meet the criteria for aforementioned diagnoses were diagnosed as functional bloating.
Medication record was searched for rifaximin treatment for abdominal bloating. The response rate to rifaximin treatment was determined by examining the follow-up medical record.
The self-reported severity score, as described for abdominal distension/tightness, was used to evaluate the effectiveness.
The severity scoring questionnaire is described elsewhere.
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Response to treatment was defined as having more than 50% improvement in the subjective score, four weeks after the cessation of treatment. The change in symptom after adding rifaximin to each patient's regimen was specifically recorded.
Abdominal simple X-ray
Those with bloating at the time of visitation to the clinic underwent abdominal X-ray. Examinations for interpretation were randomly assigned to three radiologists who were blinded to clinical information. The formal report of radiologist Values are presented as n (%). BMI, body mass index; F/U, follow-up; Sx., symptom. 
RESULTS
Baseline demographics
Sixty-three patients without organic diseases were enrolled.
The average age was 56.8±14.2 years. Among them, 76.1%
of the patients were older than 50 years (Table 1) . Thirty-one out of the total 63 patients were female (49.2%). Among the 26 patients with the available records of abdominal X-ray, 10
had gas distension or feces retention with mild ileus, as documented by a radiologist. The average duration of bloating symptom before the prescription of rifaximin was 24.0 months ( Table 1 ).
According to the Rome III criteria, there were 22 patients The Korean Journal of Gastroenterology Values are presented as n (%). BMI, body mass index. 
X-ray findings
Out of the 26 patients with X-ray records, 10 patients (38.5%) showed remarkable X-ray findings, such as gaseous distension or feces retention with mild ileus (Table 2) . Irritable bowel syndrome with constipation (IBS-C) group showed relatively high proportion of remarkable X-ray finding (5 out of 8 patients, 62.5%); however, the difference between the IBS-C group and others was not statistically significant (p=0.099, compared to other groups).
Response rate according to diagnosis
Excluding the 12 patients who were lost to follow-up, a total of 51 patients were analyzed. In the IBS-C group, the response rate was relatively low (41.7%) compared with the other diagnostic groups (50-54.5%); however, the difference was not statistically significant (p=0.460) ( Table 2 ).
The proportion of females was higher in the non-response group than in the response group; however, without statistical significance (60.0% vs. 34.6%, p=0.069). Otherwise, there was no statistical difference between the response and non-response groups (p>0.05) ( Table 3) . Ten-day regimens with 800 mg or 1,200 mg showed a relatively high response rate (62.5% and 66.7%, respectively).
The lowest response rate was noted with 800 mg for 14 days (total 11,200 mg, 20%) and 1,200 mg for 14 days (total 16,800 mg, 25%). However, no statistical significance was noted between the groups (p=0.537) ( Table 4 ). The degree of improvement was not significant between the groups (p=0.841).
DISCUSSION
Abdominal bloating is a widely prevalent and bothersome symptom in patients of all ages. Patients experience gaseous distension, not only in those with organic diseases but also in those with IBS and other FGIDs. It is a common complaint worldwide, with the prevalence of over 15% both in Asia and USA. [13] [14] [15] There have been many studies trying to explain the pathophysiology and to provide treatment; however, the exact pathophysiology of bloating remains unclear. 2, 3 The relationship between bloating and actual abdominal distension was also investigated; however, only half of patients with bloating had demonstrable increase in girth. 16 Among many other possible etiologies, such as psychologic tendency, altered gut motility, visceral hypersensitivity, and malabsorption, the impact of gut microbiome has been studied extensively.
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Based on studies showing a relationship between gut microbiota and bloating, rifaximin -a non-absorbable antibiotic -has been proposed as a possible therapy for treating bloating due to gut microbiota. 18, 19 This antibiotic has been suggested to reduce the amount of abdominal gas by decreasing abnormal bacterial fermentation. 20 Rifaximin was also reported to have an eradication rate for bacterial overgrowth as high as 70%. 21 There have been several clinical reports with various dosage and treatment duration. [22] [23] [24] However, there is no widely accepted guideline or recommendation for the use of rifaximin for bloating, as reflected by the Japanese health insurance system not covering antibiotics to be used for the purpose. 25 In the current study, the mean age of enrolled patients was 56. . 26 In a meta-analysis focus on the efficacy and safety of rifaximin for IBS, age was a significant factor associated with the improvement of global IBS symptoms (correlation coefficient, 0.97). 27 The study reported that older patients had higher rates of improvement. 27 The response rate to rifaximin was 51.0% in our study. In the meta-analysis, the pooled odds ratio for the improvement of bloating was 41.6 compared with 31.7 in the placebo group. 27 The higher rate of improvement in our study could partly be attributed to the enrollment of patients with relatively high age. This necessitates further large-scale study to confirm our findings.
Although plain abdominal film is a simple and noninvasive method to identify intraluminal gas, 28 to the best of our knowledge, there is no specific guideline for conventional radiography in FGID according to systemic review articles. 29, 30 In contrast to the cases of acute abdominal pain, 31 there is no widely accepted relevant radiologic findings for FGID.
There have been efforts to objectively describe the amount of abdominal gas in FGID patients using simple X-ray; however, they reported mixed results. One of the studies measured gas bubble to be more than 1 cm in diameter to quantify bowel gas area (BGA). 32 It reported higher BGA in the constipation-predominant IBS and unspecified functional bowel disorder patients than the control group (p<0.01); but, BGA did not correlate with symptoms. 32 Another study employed a gas volume score (GVS) by calculating the pixel value on images and found significantly higher GVS of IBS patients than the control group (p<0.001). 33 However, a research on subjective symptom and GVS failed to report a significant correlation between them. 34 Another study using GVS also found no difference between IBS patients and the control group. 35 There was no significant relationship between GVS and organic acid or bacterial counts as well. 35 As there is no universally accepted plain X-ray finding for FGID, we defined 'remarkable' film as 'gaseous distension' or 'feces retention with mild ileus'. We found specific X-ray reports in 38.5% of patients with bloating. Among them, IBS-C patients showed the highest proportion of patients with abnormal X-ray. Although the number of cases is small, this is a similar finding to the previous report with IBS-C patients.
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A future large-cale study with IBS-C patients could be helpful to prove the utility of plain film in the population. Our result of X-ray may be limited in that not every patient underwent X-ray because it was performed only for those with symptoms, such as abdominal distension at the time of visit. It could be meaningful if the plain films were compared before and after the treatment to investigate the effects of treatment on the image and correlated it with the symptom.
Our study was designed to investigate the effect of rifax- The mechanism of rifaximin in FGID is complex. Its direct effect on bacteria and virulence factors, as well as indirect effects like reduction of mucosal inflammation, had been documented. 38 There was a molecular approach to explain the effect of rifaximin for non-constipated IBS patients based on gut microbiota modulation. 39 Rifaximin treatment relieved IBS symptom; however, it did not show any shifts in the overall composition of microbiota. 39 It implied other mechanisms of action by rifaximin, as suggested by an animal study, such as prevention of gut inflammation and visceral hyperalgesia, 
